Differential effects of β-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol

Circulation

Volumn 102, Issue 5, 2000, Pages 546-551

  Metra, Marco ^a,b   Giubbini, Raffaele ^b   Nodari, Savina ^a   Boldi, Emiliano ^a   Modena, Maria Grazia ^c   Cas, Livio Dei ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b SPEDALI CIVILI   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Heart failure; Hemodynamics; Receptors, adrenergic, beta

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; DIGOXIN; ENALAPRIL; FUROSEMIDE; METOPROLOL;

ADULT; ARTICLE; ARTIFICIAL HEART PACEMAKER; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART STROKE VOLUME; HUMAN; HYPOTENSION; LONG TERM CARE; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; VERTIGO;

EID: 0034255060     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.5.546     Document Type: Article

References (28)

1. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
2. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
3. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
4. Consensus Recommendations for the management of chronic heart failure, II: Management of heart failure: Approaches to the prevention of heart failure
5. Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy
6. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart
7. Mechanism of action of beta-blocking agents in heart failure
8. Beta-adrenergic blockade in chronic heart failure: Principles, progress, and practice
9. Pharmacology of carvedilol: Rationale for use in hypertension, coronary artery disease, and congestive heart failure
10. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol
11. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure
12. Beta-blockade in heart failure: A comparison of carvedilol with metoprolol
13. Measurement of absolute left ventricular volume from gated blood pool studies
14. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy
15. Use of cardiopulmonary exercise testing with hemodynamic monitoring in the prognostic assessment of ambulatory patients with chronic heart failure
16. The 6-minute walk a new measure of exercise capacity in patients with chronic heart failure
17. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity using a randomized, double-blind, placebo-controlled trial of pimobendan
18. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
19. Randomised placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease
20. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade
21. Impaired chronotropic response to exercise in patients with congestive heart failure: Role of post-synaptic β-adrenergic desensitization
22. Role of beta-adrenergic down-regulation in the peak exercise response of subjects with heart failure due to idiopathic dilated cardiomyopathy
23. Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure
24. Combined alpha-beta blockade compared to beta blockade alone in congestive heart failure
25. Maximal and submaximal exercise esting in heart failure
26. Controlled release metoprolol: Clinical pharmacokinetic and therapeutic implications
27. Controlled release metoprolol formulations: A review of their pharmacokinetic properties, and therapeutic use in hypertension and ischemic heart disease
28. Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure